Community Investing Ideas

Global Weekly Picks

US$726.29
FV
32.7% overvalued intrinsic discount
7.00%
Revenue growth p.a.
2.4k
users have viewed this narrative
9users have liked this narrative
2users have commented on this narrative
20users have followed this narrative
CA$25.33
FV
23.3% undervalued intrinsic discount
8.00%
Revenue growth p.a.
5.2k
users have viewed this narrative
14users have liked this narrative
0users have commented on this narrative
50users have followed this narrative
US$39.99
35.4% undervalued intrinsic discount
Coward_Nutlick's Fair Value
Revenue
35.69% p.a.
Profit Margin
21.21%
Future PE
29.38x
Price in 2030
US$55.82
US$532.46
0.5% overvalued intrinsic discount
Tokyo's Fair Value
Revenue
12% p.a.
Profit Margin
30%
Future PE
50x
Price in 2031
US$738.89
ELTX logo
Elicio Therapeutics

Very Bullish

98% of pancreatic cancer patients in Phase II study generated powerful immune responses to the KRAS antigens. Median T-cell immune response above threshold was 44-fold.Read more

View narrative
197
users have viewed this narrative
4users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
US$100
91.8% undervalued intrinsic discount
Coward_Nutlick's Fair Value
Profit Margin
21.21%
Future PE
29.38x
Price in 2031
US$140.1